1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Melanoma - Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026

  • October 2017
  • 30 pages
  • ID: 3008636
In this report:
In the ##MM, GlobalData epidemiologists forecast the diagnosed incident cases of melanoma to increase from ##,## cases in 2016 to ##,## cases in 2026, at an Annual Growth Rate (AGR) of ##.##%.
The five-year diagnosed prevalent cases of melanoma in the ##MM are also expected to increase from ##,## cases in 2016 to ##,## cases in 2026 at an AGR of ##.##%.

Summary

Table of Contents

Search Inside

EpiCast Report: Melanoma - Epidemiology Forecast to 2026

Brief

Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013).

In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate of almost 2.50 percent. The U.S. will have the more important number of melanoma cases throughout the forecast period. The 5-year diagnosed prevalent cases of melanoma in the 7MM are also anticipated to increase from almost 0.75 million cases in 2016 to over 900,000 cases in 2026 at an AGR of over 2.50 percent.

Australia (AU) has the more considerable age-standardized incidence rate of melanoma in the 7MM by a meaningful margin. In 2016, incidence of melanoma in Australian men was over 60 cases per 100,000, and over 41.59 cases per 100,000 in Australian women. The second more significant age-standardized incidence of melanoma in men was in the U.S., at about 30 cases per 100,000 of its population. The United Kingdom (UK) had the second more important incidence rate in women, at about 20 cases per 100,000. Over the forecast period, the age-standardized incidence rates of melanoma will remain largely unchanged, with the greatest growth seen in Germany (DE) from 2006-2011.

The market research "EpiCast Report: Melanoma - Epidemiology Forecast to 2026", offers an overview of the risk factors, comorbidities, and the overall and historical trends for melanoma of the skin in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Australia (AU)). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma divided by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).

Overview

- The Melanoma EpiCast Report offers an overview of the risk factors and overall trends of melanoma in the 7MM (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Australia (AU)). It includes a 10-year epidemiological forecast for the diagnosed incident cases and 5-year diagnosed prevalent cases of melanoma broken down by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).

- The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The Melanoma EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall melanoma market.

- Quantify patient populations in the overall melanoma market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for melanoma therapeutics in each of the markets covered.

- Compare patient population potentials by age, sex, stage at diagnosis, and survival.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Gastrointestinal / GI Stent Market by Type Material Disease, End User - Global Forecast to 2022

Gastrointestinal / GI Stent Market: Global Forecast until 2022

  • $ 5650
  • Industry report
  • December 2017
  • by MarketsandMarkets

The gastrointestinal stents market is projected to grow at a CAGR of 5.1% between 2017 and 2022.The gastrointestinal stents market is expected to reach USD 452.6 million by 2022 from USD 353.4 million ...

Cancer/Tumor Profiling Market by Application, Technique ,Technology - Forecast to 2021

Cancer/Tumor Profiling Market: Forecast until 2021

  • $ 5650
  • Industry report
  • January 2018
  • by MarketsandMarkets

The global cancer/tumor profiling market is projected to grow at a CAGR of 10.7%.Global cancer/tumor profiling market is projected to reach USD 8.74 billion in 2022 from USD 5.26 billion in 2017 at CAGR ...

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • January 2018
  • by Infiniti Research Limited

About Gene TherapyOvarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cance ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.